Drugs / UMIROLIMUS
UMIROLIMUS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03952273 | Aug 2019 → Mar 2023 overdue | coronary artery disorder | Phillip Freeman | Active not recruiting | Met primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UMIROLIMUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107380 ↗ |
| Known as | 40-o-(2-ethoxyethyl)rapamycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107380 ↗ |
| Known as | 42-o-(2-ethoxyethyl) rapamycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107380 ↗ |
| Known as | Biolimus | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107380 ↗ |
| Known as | biolimus A9 | “The biodegradable polymer Biomatrix Alpha stent contains biolimus A9 drug which is a sirolimus derivative increased in lipophicity.” PMID 39870125 ↗ Jan 2025 |
| Known as | Rapamycin, 42-o-(2-ethoxyethyl)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107380 ↗ |
| Known as | TRM 986 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107380 ↗ |
| Modality | Small molecule | — CHEMBL2107380 ↗ |